Varicella Zoster
9
0
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
22%
2 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
Clinical Features and Outcomes of VZV CNS Infections
Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients
ACTIVATE in Public Housing
Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT
Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
Safety of Zostavax Vaccination in Rheumatoid Arthritis
Reactivation of Varicella Zoster Virus and Risk of Vascular Disease
Tzanck Smear With Methylene Blue Stain for Herpes
Safety Study of NBP608 in Healthy Adult Volunteers